New research has shown the effectiveness of OXO-001, a first-in-class oral drug, in increasing embryo implantation, pregnancy, and live birth rates in infertile women undergoing IVF or ICSI. The study, presented at the ESHRE 40th Annual Meeting, marks a significant advancement in improving success rates in assisted reproduction. The drug acts directly on the endometrium to enhance embryo implantation and pregnancy rates. Results from the Phase II clinical trial showed significant improvements in pregnancy and live birth rates among women who received OXO-001 compared to a placebo. The drug was well-tolerated with minimal side effects, giving hope to patients and the scientific community.
Source link
Novel treatment improves embryo implantation and live birth rates in infertile women undergoing IVF and ICSI
